3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Hyperglycemia
1
Breast Neoplasms
1
Interventions
lutetium Lu 177 dotatate
31
Magnetic Resonance Spectroscopy
25
pembrolizumab
21
Specimen Handling
18
Nivolumab
17
cabozantinib
14
lenvatinib
12
Everolimus
12
trametinib
11
gallium Ga 68 dotatate
10
dabrafenib
10
Ipilimumab
10
Carboplatin
10
Cisplatin
8
atezolizumab
7
Temozolomide
7
Lutetium-177
7
Capecitabine
7
X-Rays
6
Etoposide
6
surufatinib
5
olaparib
5
lanreotide
5
fluorodopa F 18
5
cemiplimab
5
Vemurafenib
5
Paclitaxel
5
Octreotide
5
Lutetium
5
Fluorodeoxyglucose F18
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vildagliptin
×
Endocrine
×
1 year
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled